Degarelix and its therapeutic potential in the treatment of prostate cancer

Christian Doehn, Martin Sommerauer, Dieter JochamDepartment of Urology, University of Lübeck Medical School, Lübeck, GermanyAbstract: Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of patients with prostate cancer in whom hormonal therapy is indic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christian Doehn, Martin Sommerauer, Dieter Jocham
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Prostate cancer hormonal therapy GnRH antagonist degarelix testosterone flare Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/1b3742e3cb0242a6b385e05f965fe3bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1b3742e3cb0242a6b385e05f965fe3bc
record_format	dspace
spelling	oai:doaj.org-article:1b3742e3cb0242a6b385e05f965fe3bc2021-12-02T04:06:10ZDegarelix and its therapeutic potential in the treatment of prostate cancer1178-1998https://doaj.org/article/1b3742e3cb0242a6b385e05f965fe3bc2009-05-01T00:00:00Zhttps://www.dovepress.com/degarelix-and-its-therapeutic-potential-in-the-treatment-of-prostate-c-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Christian Doehn, Martin Sommerauer, Dieter JochamDepartment of Urology, University of Lübeck Medical School, Lübeck, GermanyAbstract: Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of patients with prostate cancer in whom hormonal therapy is indicated. Two phase II trials and one phase III have been published as full papers in the literature. In the dose-finding phase II studies an initial dose of 240 mg degarelix sc followed by a monthly injection of 80 mg or 160 mg degarelix sc was sufficient to keep testosterone levels ≤ 0.5 ng/ml. In a phase III trial it was demonstrated that degarelix was not inferior (in terms of testosterone suppression and prostate-specific antigen [PSA] decline) compared to standard hormonal therapy, ie, a GnRH agonist such as leuprolide. In fact, degarelix was associated with a faster testosterone suppression and PSA decline than leuprolide. Adverse events such as pain at the injection site (40% vs <1%) and chills (4% vs 0%) were more commonly associated with degarelix. Also, degarelix is currently only available as one-month depot whereas in daily practice three-month depots (of GnRH agonists) are the preferred regimen. However, degarelix was recently approved by the US Food and Drug Administration for the treatment of advanced prostate cancer.Keywords: prostate cancer, hormonal therapy, GnRH antagonist, degarelix, testosterone, flareChristian DoehnMartin SommerauerDieter JochamDove Medical PressarticleProstate cancerhormonal therapyGnRH antagonistdegarelixtestosteroneflareGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 4, Pp 215-223 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Prostate cancer hormonal therapy GnRH antagonist degarelix testosterone flare Geriatrics RC952-954.6
spellingShingle	Prostate cancer hormonal therapy GnRH antagonist degarelix testosterone flare Geriatrics RC952-954.6 Christian Doehn Martin Sommerauer Dieter Jocham Degarelix and its therapeutic potential in the treatment of prostate cancer
description	Christian Doehn, Martin Sommerauer, Dieter JochamDepartment of Urology, University of Lübeck Medical School, Lübeck, GermanyAbstract: Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of patients with prostate cancer in whom hormonal therapy is indicated. Two phase II trials and one phase III have been published as full papers in the literature. In the dose-finding phase II studies an initial dose of 240 mg degarelix sc followed by a monthly injection of 80 mg or 160 mg degarelix sc was sufficient to keep testosterone levels ≤ 0.5 ng/ml. In a phase III trial it was demonstrated that degarelix was not inferior (in terms of testosterone suppression and prostate-specific antigen [PSA] decline) compared to standard hormonal therapy, ie, a GnRH agonist such as leuprolide. In fact, degarelix was associated with a faster testosterone suppression and PSA decline than leuprolide. Adverse events such as pain at the injection site (40% vs <1%) and chills (4% vs 0%) were more commonly associated with degarelix. Also, degarelix is currently only available as one-month depot whereas in daily practice three-month depots (of GnRH agonists) are the preferred regimen. However, degarelix was recently approved by the US Food and Drug Administration for the treatment of advanced prostate cancer.Keywords: prostate cancer, hormonal therapy, GnRH antagonist, degarelix, testosterone, flare
format	article
author	Christian Doehn Martin Sommerauer Dieter Jocham
author_facet	Christian Doehn Martin Sommerauer Dieter Jocham
author_sort	Christian Doehn
title	Degarelix and its therapeutic potential in the treatment of prostate cancer
title_short	Degarelix and its therapeutic potential in the treatment of prostate cancer
title_full	Degarelix and its therapeutic potential in the treatment of prostate cancer
title_fullStr	Degarelix and its therapeutic potential in the treatment of prostate cancer
title_full_unstemmed	Degarelix and its therapeutic potential in the treatment of prostate cancer
title_sort	degarelix and its therapeutic potential in the treatment of prostate cancer
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/1b3742e3cb0242a6b385e05f965fe3bc
work_keys_str_mv	AT christiandoehn degarelixanditstherapeuticpotentialinthetreatmentofprostatecancer AT martinsommerauer degarelixanditstherapeuticpotentialinthetreatmentofprostatecancer AT dieterjocham degarelixanditstherapeuticpotentialinthetreatmentofprostatecancer
_version_	1718401416315273216

Degarelix and its therapeutic potential in the treatment of prostate cancer

Ejemplares similares